|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| License agreement receivable | ||||||||||||||||||||
| License agreement contract asset | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Asset Purchase Agreement payable (Note 10) | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Other liabilities, current portion (See Note 8) | ||||||||||||||||||||
| Operating lease liability, current portion | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Convertible debt and derivative liability (Note 6) | ||||||||||||||||||||
| Convertible debt | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Convertible debt and derivative liability (Note 6) | ||||||||||||||||||||
| Loan payable (Note 8) | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.001 par value, authorized 5,000,000 shares as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.001 par value, 60,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 9,949,609 and 5,442,688 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
